In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses future industry trends live from AAPS Boston 2022, with:

• Casey Franklin, VP of Business Development at Alcami

• Umberto Romeo, R&D Manager at Corden Pharma

• Steven Dodd, Executive Director for sales strategy at Icon CRO

• Paul Dickinson, Founder & CSO at Seda Pharmaceutical Development Services

Raman finds out more about the exciting opportunities coming up for these companies in 2023 and beyond, as well as scoring the inside scoop on trends our guests foresee both within their business and the wider industry. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Katz, Founder & CSO at Sparrow Pharmaceuticals, Inc.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• The contrast of developing new drugs and running clinical trials in a big pharma versus his journey as the founder of a virtual biopharma company.

Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan, earned MPhil and PhD degrees in Molecular Biophysics and Biochemistry from Yale University, and is an alumnus of Pomona College (BA, Chemistry). David has published over 50 peer-reviewed scientific papers and in his copious spare time, he is actively involved in new play development and is a glass artist.

Don't forget to subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason McKenna, Global President, and Dean McAlister, Executive Vice President both from Inizio Biotech.

• A wealth of big pharma learnings for today’s emerging biotechs.

Jason spent the initial part of his career in big pharma, working for AstraZeneca in the US and UK across a variety of marketing, sales and finance roles. He is now the Global President of Inizio’s first enterprise business unit, Inizio Biotech. Jason and his team enable biotech partners to maximize the value of their assets by providing scalable support, through the seamless experience of a single point of coordination. Previously CEO at STEM, an Inizio Advisory company, Jason led the organization through significant scaling and transformation throughout the COVID pandemic.

Dean has over 35 years of biopharma experience across established and startup organizations – including 28 years with AstraZeneca in 16 roles of increasing commercial responsibility, where he led global and regional sales and strategic business development. Dean has built cross-functional teams spanning all therapeutic areas. Following AZ, he grew STEM Healthcare North America from 10 clients to 38 over a five-year period before a sale to UDG. He is also a podcaster, speaker, and published author.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special episode of Molecule to Market, we go back inside the global drug development space with Marcelo Bigal, President and CEO, of Ventus Therapeutics, and Versant Venture Partner, who shares his journey from being a neurologist to taking a drug to market when he became part of Teva Pharmaceuticals and now is a CEO.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcelo, covering: 

• What it feels like to take a drug from the laboratory to market and what really goes into that process.

Marcelo brings more than 13 years of pharma experience with a focus on urology spanning r&d, medical and scientific affairs. He has extensive experience in leading large and small scientific groups, including multiple leadership roles in industry, including the Chief Scientific Officer at Teva as well as Chief Medical Officer at Teva and Purdue. Prior to his work in the pharma sector, Marcelo was a faculty member of the Albert Einstein College of Medicine, Department of Neurology, as well as the director of research at the New England Centre for headache. 

He has authored no fewer than 330 papers in peer-reviewed journals, edited six books in urology and is the recipient of multiple awards and recognitions in the field. Marcelo holds a medical doctorate degree from the College of Medicine at the University of Sao Paulo, Brazil, where he obtained a master’s in science and a PhD in neurosciences. He completed his postdoctoral research at the New England Centre for headache.

In this special repurposed episode of Molecule to Market, we go back inside the global drug development space with previous guests Magnus Gustafsson, Board Member at Genovis, Jeff Dill, CEO at Vynamic. , and Peter Soelkner, Managing Director at Vetter to hear their thoughts on building a great organisational culture. 

Your host, Raman Sehgal, revisits discussions from past episodes, with amazing global guests who share their insights about building culture to give our listeners loads of takeaway points, from episodes including:

• Finland’s Viral Vector Manufacturer of Happinesses
  

• Creating a healthy culture
  

• From Pharmacy to $1B family-owned CDMO
  

Raman enjoyed the original conversations and took pleasure in listening back to bring you this special culture themed episode. It’s clear our guests all agree that culture is key to developing and scaling a great organization.

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Evelyn Kelly, Chief Executive Officer at Orphan Drug Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Evelyn, covering:

• A deep dive into the world of orphan drugs, rare diseases and personalised medicines including the background, evolution and fast growth of the area.

Evelyn has over 15 years’ experience in the pharmaceutical industry in both distribution and orphan drug companies, working across supply chain, quality assurance and management roles. Evelyn brings years of experience in manufacturing and distributing orphan and speciality drugs to over 50 countries globally.She specializes in the management of supply via virtual, outsourced models and has been named as both a QP and RP on multiple licenses. She has held various positions in Shire, NPS Pharma and PTC Therapeutics and has designed and ran successful supply chains for different products.Evelyn founded Orphan Drug Consulting in 2017, with the vision of supporting companies across the drug development cycle. She holds a Master of Pharmacy from Robert Gordon University and a Master of Business from the Irish Management Institute. She also acts as Adjunct Associate Professor for the School of Pharmacy, Trinity College, Dublin. In 2022, she was named as a finalist in EY Entrepreneur of the Year.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chuck Frey, VP Scientific Affairs at Coating Place. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chuck, covering:

• The backstory to Wurster coating technology and how it changed the world of formulation development.

Charles (Chuck) Frey is the Vice President of Scientific Affairs at Coating Place, Inc., a CDMO focused in Wurster (bottom spray) fluid bed coating and associated services.Chuck moved on to Coating Place, Inc. in 1999 to develop expertise on the Wurster fluid bed coating process. During his time at Coating Place, Chuck has focused primarily on application of the Wurster process and related technologies to meet the feasibility, formulation development, scale up, validation, and commercial processing needs of clients. Primary interests have included both formulation chemistry and optimization of process dynamics. The company continues to manufacture proprietary Wurster coating equipment for its operations and Chuck has helped maintain and expand the company’s offer with new fluidization plate designs, new nozzles, enhanced scaling knowledge, and other technical advancements. Having spent over 30 years in the sector, Chuck has also lectured on the Wurster process and formulations, and contributed several book chapters on the fluid bed coating processes and formulations.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, Consulting CFO, Special Advisor & Board Member of several biotech companies. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:

• The sensitive cash position of biotech's as a ‘hangover’ after a decade of partying as the market was high.

Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audit and two compensation committees. He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special episode of Molecule to Market, we go back inside the global drug development space with previous guests Go van Dam, CEO & Founder at TRACER,  Michelle Duggan, Inward Investment Manager, Invest North East England, Peter Soelkner, Managing Director at Vetter and Ross Burn, Chief Executive at CatSci.

• Physician. Scientist. Entrepreneur.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adrienne Leussa, Director of Ecosystem Partnerships at 54gene.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adrienne, covering:

• How the reality of the health challenges living in Africa as a child drove Adrienne into the drug discovery space.

Adrienne is a Biochemist (PhD) with 10+ years of hands-on experience and a plethora of diverse technical skills within the area of drug discovery and development. She has also worked as a lecturer and researcher in top African universities helping inspire a generation of scientists through access to information on the applications of biotechnology.She is fluent in 3 of the most used languages in Africa: Portuguese, French and English, and is ardent about continued learning, cross-culture collaboration, problem solving, customer service and mentoring.Adrienne’s mission is to elevate Africa through high quality, innovative, and credible scientific output for global prosperity.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.